Radiomer Jagruti is an accomplished biomedical researcher with nearly a decade of experience in drug discovery, preclinical development, and project management. over 30 years research, product development and operations experience at large and startup company settings. Novel radiopharmaceutical radioligand therapy platform that leverages raptamersᵀᴹ (peptide oligonucleotide hybrids) as a targeting moiety vector.
Radiomer Radiomer therapeutics's chief medical officer is philip breitfeld. other executives include sougata dey, director of chemistry; michael j. heffernan, vice president of operations and 2 others. see the full leadership team at craft. Radiomer therapeutics is a biotechnology research company located in houston, texas with 5 employees. find top employees, contact details and business statistics at rocketreach. Radiomer therapeutics, targeted radiopharmaceutical therapies for theranostic cancer applications. here you'll find information about their funding, investors and team. Find contact information for radiomer. learn about their medical laboratories & imaging centers, healthcare services market share, competitors, and radiomer's email format.
.jpg "Team Radiomer")
Team Radiomer Radiomer therapeutics, targeted radiopharmaceutical therapies for theranostic cancer applications. here you'll find information about their funding, investors and team. Find contact information for radiomer. learn about their medical laboratories & imaging centers, healthcare services market share, competitors, and radiomer's email format. We are always looking for ambitious people to join our team. you'll have opportunities to learn quickly, advance your career, and to meaningfully impact our customers and our business. click here to learn about careers. Radiomer therapeutics focuses on developing a radiopharmaceutical platform within the biotechnology sector. the company specializes in creating radioligand therapies that utilize raptamers, which are peptide oligonucleotide hybrids, to target specific cells for treatment. Dr. varadhachary: we have three radiomers with pre clinical anti cancer data, and many others earlier in development. two of our more advanced programs are against what we call first in class targets, those for which there are no approved drugs, while the third is against a well known target. Company profile page for radiomer therapeutics inc including stock price, company news, executives, board members, and contact information.
Comments are closed.